DERMJourney Medical Corporation
The schedule
- Wed30Sep
Key 2026 payer reimbursement and formulary decisions for Journey Medical’s dermatology portfolio, where favorable coverage and tier placement could support DERM around $8.30 from a $7.70 base, while restricted access or higher patient cost-sharing could drag shares back toward $8.30.
- Thu15Oct
Launch of a competing branded dermatology therapy that could pressure Journey Medical’s prescription volumes and pricing, with strong competitive displacement risking a move in DERM from $8.30 down toward $7.60, while a benign launch or differentiated positioning would likely limit damage to around $7.60.
- Tue15Dec
Update on any ongoing class-action or securities fraud investigation involving Journey Medical, where dismissal or limited settlement exposure could stabilize DERM around $4.90, but adverse rulings, expanded claims, or larger-than-expected settlement ranges could drag the stock toward $4.90 from $4.40.
- Fri15Jan
Potential acquisition or in-licensing of an additional commercial dermatology asset, where an accretive transaction with reasonable deal terms could re-rate DERM from $3.00 toward $4.00, while overpaying for a low-quality or dilutive asset could push shares down toward $4.00.
- Tue9Feb
Q3 2026 earnings, which will be scrutinized for proof that Journey Medical can transition to consistent profitability; clear evidence of operating leverage could move DERM from $5.80 toward $6.90, while stalled margin progress or guidance disappointment could pressure shares toward $6.90.
- Mon10May
Full-year 2026 earnings and the 2027 outlook, where confirmation of sustainable growth and visibility to breakeven could lift DERM from $4.00 toward $5.30, while cautious 2027 guidance or renewed losses could send shares back toward $5.30.
- Wed12May
Q1 2027 earnings, offering the first checkpoint on whether Journey Medical is executing against its 2027 plan; a strong start with improving profitability could nudge DERM from $3.10 toward $3.80, while early misses or higher-than-expected spend would likely pressure the stock toward $3.80.
Past
- Tue11Aug
Actual outcome: Bull
Journey Medical reported Q2 2026 EPS of -$0.08, perfectly matching Wall Street estimates. The stock rose 5.1% following the release, as the in-line earnings and management's commentary during the earnings call reassured investors regarding the company's sustained dermatology revenue growth and loss-narrowing trajectory. The positive reception of key underlying metrics and stable guidance drove the stock higher.
Q2 2026 earnings and mid-year guidance from Journey Medical, where sustained double-digit dermatology revenue growth and further loss narrowing could lift DERM from $6.85 toward $7.70, while any slowdown in Emrosi-driven sales or weaker 2H outlook risks a reset toward $7.70.
- Tue30Jun
Actual outcome: Bull · $7.27 at outcome
Journey Medical did not execute a dilutive secondary equity offering during the target period, removing a key near-term overhang on the stock. The absence of immediate dilution allowed shares to appreciate well above the bull target, as investors gained confidence in the company's current balance sheet and capital strategy.
Risk that Journey Medical executes a secondary equity offering to bolster its balance sheet, which could pressure DERM from $6.85 toward $6.20 if terms are dilutive, or keep shares closer to $6.20 if management defers or pairs any raise with value-accretive use of proceeds.
- Wed13May
Actual outcome: Bull · $6.06 at outcome
Journey Medical reported a 21% year-over-year increase in Q1 revenue to $16.0 million, beating estimates, alongside a significantly narrowed net loss of $0.08 per share compared to $0.18 a year ago. The strong top-line growth, driven by $6.3 million in Emrosi sales, and an increased cash position of $27 million fulfilled the bull case expectations. This evidence of narrowing operating losses and strong financial performance drove the stock higher toward the bull target by the run date.
Q1 2026 earnings on 2026-05-13 will be the first full look at Journey Medical’s dermatology portfolio after the sharp swing back to losses in 2025, with the stock at $5.33 into the print. A clean beat on revenue growth and evidence that operating losses are narrowing could support a move toward $6.30, while another quarter of negative EPS and cash burn acceleration would likely push shares toward $6.30 as investors reassess the path to sustainable profitability.
